Difficulty: Medium
Average Score: 73%
Practice
Sulfasalazine:
Correct answer
B
Rationale
In the context of gastrointestinal drugs, understanding the mechanism of action and indications of sulfasalazine is crucial for effective clinical practice.
The correct answer is B) Is used for maintenance treatment of ulcerative colitis. Sulfasalazine is a combination of sulfapyridine and 5-aminosalicylic acid (5-ASA). It is commonly used for the maintenance treatment of ulcerative colitis due to its anti-inflammatory properties and ability to reduce symptoms and induce remission in this condition.
Option A) Is a prodrug is incorrect because sulfasalazine itself is the active compound, not a prodrug. It is broken down into sulfapyridine and 5-ASA in the colon by bacterial action.
Option C) Is effective in small bowel Crohn's disease is incorrect because sulfasalazine is primarily effective in treating inflammation in the colon, rather than the small bowel which is more commonly affected in Crohn's disease.
Option D) Should be avoided in glucose 6-phosphate dehydrogenase (G6PD) deficiency is incorrect because sulfasalazine does not have a direct contraindication in G6PD deficiency. However, caution may be warranted due to the potential for hemolytic anemia in patients with this deficiency.
Educationally, understanding the specific indications, mechanism of action, and potential side effects of sulfasalazine is crucial for healthcare professionals involved in the management of gastrointestinal conditions. This knowledge allows for appropriate selection of medications based on individual patient characteristics and disease pathology, ultimately optimizing patient outcomes.
The correct answer is B) Is used for maintenance treatment of ulcerative colitis. Sulfasalazine is a combination of sulfapyridine and 5-aminosalicylic acid (5-ASA). It is commonly used for the maintenance treatment of ulcerative colitis due to its anti-inflammatory properties and ability to reduce symptoms and induce remission in this condition.
Option A) Is a prodrug is incorrect because sulfasalazine itself is the active compound, not a prodrug. It is broken down into sulfapyridine and 5-ASA in the colon by bacterial action.
Option C) Is effective in small bowel Crohn's disease is incorrect because sulfasalazine is primarily effective in treating inflammation in the colon, rather than the small bowel which is more commonly affected in Crohn's disease.
Option D) Should be avoided in glucose 6-phosphate dehydrogenase (G6PD) deficiency is incorrect because sulfasalazine does not have a direct contraindication in G6PD deficiency. However, caution may be warranted due to the potential for hemolytic anemia in patients with this deficiency.
Educationally, understanding the specific indications, mechanism of action, and potential side effects of sulfasalazine is crucial for healthcare professionals involved in the management of gastrointestinal conditions. This knowledge allows for appropriate selection of medications based on individual patient characteristics and disease pathology, ultimately optimizing patient outcomes.